Navigation Links
Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board
Date:11/28/2007

HAMBURG, Germany and OXFORD, England, November 28 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced that Dr Mario Polywka and Dr Klaus Maleck have been appointed to the Company's Management Board (Vorstand), as Chief Operating Officer and Chief Financial Officer.

Jorn Aldag, President & Chief Executive Officer of Evotec AG, said: "I'm extremely pleased to announce the addition of Dr Mario Polywka and Dr Klaus Maleck to our Management Board. Both are individuals with a wealth of experience and a great understanding of their respective disciplines. I am convinced they will significantly impact the further development of Evotec. Mario's appointment is recognition for his successful contributions to our Company as he played a key role in building Evotec's world-class drug discovery and development platform and reputation in the industry. Klaus joined us early 2007 with the goal of becoming CFO. With degrees in biotechnology and a MBA he has a unique blend of skills. With his past experience as CFO and Head of Business Development at BioGeneriX we expect him to be a strong leader of our Finance Team."

Dr Mario Polywka, 44, has served as Chief Operating Officer and a member of the Company's Executive Committee since 2004. Between 2002 and 2004, Dr Polywka ran a number of spin-out companies in the Oxford area, and he still serves as Chairman on the boards of Pharminox Ltd. and Glycoform Ltd. Following the merger of EVOTEC BioSystems AG with Oxford Asymmetry International plc (OAI) in 2000, he was Chief Operating Officer until 2002. Dr Polywka was a Founding Chemist of OAI in 1991. In 1999, he was appointed Chief Operating Officer and in 2001 Chief Executive Officer of OAI plc. Dr Polywka received a doctorate from the University of Oxford in mechanistic organometallic chemistry and continued at Oxford with post-doctoral studies on aspects of the biosynthesis of penicillins.

Dr Klaus Maleck, 35, has served as Exec
'/>"/>

SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
3. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
4. Evotec AG: R&D Update on 16 October 2007 Live on the Internet
5. Evotec Reports Third Quarter 2007 Results
6. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
7. Codexis Appoints Singapore Laboratories Managing Director
8. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...lands, December 2 Pepscan Holding ...cusing on protein mimicking,technology for the gen...t it,has appointed Wim E.M. Mol, Ph.D. as new Chie...sponsible for all of Pepscans corporate functions ... of the company. He brings to,Pepscan more than 20...
(Date:12/2/2009)...ael, December 2 Gamida Cell announ...inical (animal study) safety and,efficacy of a gen...eill,Cornell Medical College and Gamida Cell. The ...ias such as Cooley,s Anemia. , Gamida Cel..., ex vivo,populations of stem/progenitor cells. T...
(Date:12/2/2009)...2 /PRNewswire-Asia-FirstCall/ -- Emerald Dairy, In...n Board: EMDY), a leading,producer and distributor...,soybean products in China, today announced that t... US Food & Drink Executive, a quarterly magazi... the food and beverage industry. , The ar...
(Date:12/2/2009)...wswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ:...armaceutical company focused on endocrine therapy ...nd Drug Administration (FDA) has granted Fast Trac...nhibitor compound, perifosine (KRX-0401), for the ... Keryx Biopharmaceuticals, Inc. ("Keryx") ( KERX),...
Breaking Biology Technology:Dutch Biotech Company Pepscan Appoints New CEO 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3
...tists has performed the ultimate miniaturisation o...nucleus of an atom. This breakthrough is a key ste...e based on the fundamental theory of quantum mecha...ent technology. , In the quantum world, objects su...s simultane-ously -- that is, they could literally...
...e to $245 Million to $247 Million -, Third Quarte...million; up 73.7% from the third quarter of 2007 ...on; up 62.3% from the third quarter of 2007, ... the third quarter of 2007, -- Gross margin of ...07, -- GAAP loss per share for the quarter was ...
...mCor Systems, Inc., a,medical device company devel...M), announced today that it has signed an agreemen...ommercialize StemCor,s proprietary System,for the ...om.com/cgi-bin/prnh/20071030/STEMCORSYSTEMSLOGO ),... Hospira will manage,the clinical trial program, l...
Other Biology Technology:Memoirs of a qubit: Hybrid memory solves key problem for quantum computing 2Nuvasive Reports Third Quarter 2008 Financial Results 2Nuvasive Reports Third Quarter 2008 Financial Results 3Nuvasive Reports Third Quarter 2008 Financial Results 4Nuvasive Reports Third Quarter 2008 Financial Results 5Nuvasive Reports Third Quarter 2008 Financial Results 6Nuvasive Reports Third Quarter 2008 Financial Results 7Nuvasive Reports Third Quarter 2008 Financial Results 8Nuvasive Reports Third Quarter 2008 Financial Results 9Nuvasive Reports Third Quarter 2008 Financial Results 10Nuvasive Reports Third Quarter 2008 Financial Results 11Nuvasive Reports Third Quarter 2008 Financial Results 12StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists 2StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists 3
(Date:12/2/2009)...d to secondhand cigarette smoke have an increased ...if they never smoked. , Results of this study a... Prevention , a journal of the American Associatio...o focus in the December issue. , This year alon...ith lung cancer; more than 159,000 will die from i...
(Date:12/2/2009)...oke their first cigarette within minutes after wak...roduct of nicotine when processed by the body, tha...r of cigarettes smoked. , "Since cotinine lev... results suggest that smokers who smoke immediatel...cancer," said researcher Joshua E. Muscat, Ph.D., ...
(Date:12/2/2009)...Smoky Mountain forest,s woodland herb population h...t understories recover from logging, according to ...ing in portions of the forest nearly 80 years ago,...ary forest floor was similar to that of undisturbe...ssor of forestry and natural resources, said that ...
Breaking Biology News(10 mins):Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Increased nicotine levels detected in those who light-up earlier 2Study finds logging effects vary based on a forest's history, climate 2Diplomat Specialty Pharmacy Continues to Expand Opens Location in Southern California 6345 1Diplomat Specialty Pharmacy Continues to Expand Opens Location in Southern California 6345 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety 6341 1Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety 6341 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety 6341 3Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety 6341 4Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety 6341 5Guided Care receives Award for Innovation in Practice Improvement 61538 1Guided Care receives Award for Innovation in Practice Improvement 61538 2
...their surprise that a drug commonly used to treat ...owth of new blood vessels commonly seen in cancers...for human use, which may fast-track its availabili... to have excess blood vessel growth, treatment wit...ercent compared to placebo. “We were surprised, to...
...vel have on the activation of the female brain? Us...aude Dreher, a researcher at the Cognitive Neurosc...ation with an American team from the National Inst...ed by Karen Berman, has identified, for the first ...eward-related functions modulated by female gonada...
...ave deduced how bony fishes conquered the oceans b...ng their eggs with the water of life ?the degradat...nes causes the eggs to fill with vital water and f...t marine teleosts that showed an unprecedented rad...ene Periods. The work is a unique hypothesis that ...
Other Biology News:Anti-fungal drug stops blood vessel growth 2The influence of the menstrual cycle on the female brain 2The influence of the menstrual cycle on the female brain 3The influence of the menstrual cycle on the female brain 4How fish conquered the ocean 2How fish conquered the ocean 3
...olecule of fascination, being the prime precursor ...such as ACTH, -Lipotrophin (-LPH), -endorphin, Alp.... It is also a very well-conserved molecule, being...e "living fossils", the lungfish. The IDS POMC ELI...
Mouse Anti-Rat Pan-NMDA NR1 Monoclonal Antibody, Unconjugated, Clone R1JHL from Calbiochem
BRASMC (B950-05) from European Collection of Cell Cultures (ECACC)
T4 DNA Ligase from Promega
Biology Products: